Skip to main content

Table 5 Fecal SCFAs in children sampled when treatment-naĂ¯ve and during treatment with MTX or ETN

From: Fecal microbiota in children with juvenile idiopathic arthritis treated with methotrexate or etanercept

SCFAs (mmol/L)

Treatment-naĂ¯ve (n = 15)

MTX (n = 15)

p value*

Treatment-naĂ¯ve (n = 7)

ETN (n = 7)

P value*

Acetate

58.6 (36.9)

49.1 (26.0)

0.57

47.5 (25.1)

43.2 (18.4)

0.61

Propionate

14.4 (7.0)

12.4 (7.0)

0.50

13.9 (8.0)

15.3 (9.1)

0.74

Isobutyrate

1.6 (1.0)

2.1 (1.4)

0.02

3.0 (4.1)

1.1 (0.6)

0.75

Butyrate

17.7 (13.9)

15.0 (10.9)

0.53

14.5 (11.8)

17.1 (10.8)

0.61

Valerate

4.3 (3.0)

4.6 (2.7)

0.44

4.8 (2.2)

5.7 (2.7)

0.50

  1. Data are mean (SE), unless otherwise indicated
  2. *Wilcoxon signed-rank test
  3. SCFAs Short-chain fatty acids, MTX Methotrexate, ETN Etanercept, SE Standard error of the mean
Back to article page

Pediatric Rheumatology

ISSN: 1546-0096